Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 6 (February 20), 2006: pp. 945-952
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.2465

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Badros, A.
Right arrow Articles by Meiller, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Badros, A.
Right arrow Articles by Meiller, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors

Ashraf Badros, Dianna Weikel, Andrew Salama, Olga Goloubeva, Abraham Schneider, Aaron Rapoport, Robert Fenton, Natalie Gahres, Edward Sausville, Robert Ord, Timothy Meiller

From the University of Maryland Marlene and Stewart Greenebaum Cancer Center; University of Maryland Dental School, Baltimore, MD

Address reprint requests to Ashraf Badros, University of Maryland, Greenebaum Cancer Center, 22 S Greene St, Baltimore, MD 21201; e-mail: abadros{at}umm.edu

PURPOSE: To describe the clinical, radiologic, and pathologic features and risk factors for osteonecrosis of the jaw (ONJ) in multiple myeloma (MM) patients.

PATIENTS AND METHODS: A retrospective review of 90 MM patients who had dental assessments, including 22 patients with ONJ. There were 62 men; the median age was 61 years in ONJ patients and 58 years among the rest. Prior MM therapy included thalidomide (n = 67) and stem-cell transplantation (n = 72). Bisphosphonate therapy included zoledronate (n = 34) or pamidronate (n = 17) and pamidronate followed by zoledronate (n = 33). Twenty-seven patients had recent dental extraction, including 12 patients in the ONJ group. Median time from MM diagnosis to ONJ was 8.4 years for the whole group.

RESULTS: Patients usually presented with pain. ONJ occurred posterior to the cuspids (n = 20) mostly in the mandible. Debridement and sequestrectomy with primary closure were performed in 14 patients; of these, four patients had major infections and four patients had recurrent ONJ. Bone histology revealed necrosis and osteomyelitis. Microbiology showed actinomycetes (n = 7) and mixed bacteria (n = 9). More than a third of ONJ patients also suffered from long bone fractures (n = 4) and/or avascular necrosis of the hip (n = 4). The variables predictive of developing ONJ were dental extraction (P = .009), treatment with pamidronate/zoledronate (P = .009), longer follow-up time (P = .03), and older age at diagnosis of MM (P = .006).

CONCLUSION: ONJ appears to be time-dependent with higher risk after long-term use of bisphosphonates in older MM patients often after dental extractions. No satisfactory therapy is currently available. Trials addressing the benefits/risks of continuing bisphosphonate therapy are needed.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Journal of the American Dental AssociationHome page
P. P. Sedghizadeh, S. K.S. Kumar, A. Gorur, C. Schaudinn, C. F. Shuler, and J. W. Costerton
Microbial Biofilms in Osteomyelitis of the Jaw and Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy
J Am Dent Assoc, October 1, 2009; 140(10): 1259 - 1265.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. N. Gebara and H. Moubayed
Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates
Am. J. Health Syst. Pharm., September 1, 2009; 66(17): 1541 - 1547.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. McMahan and T. Linneman
A Case of Resistant Hypercalcemia of Malignancy with a Proposed Treatment Algorithm
Ann. Pharmacother., September 1, 2009; 43(9): 1532 - 1538.
[Abstract] [Full Text] [PDF]


Home page
The Journal of RheumatologyHome page
A. N. LAU and J. D. ADACHI
Resolution of Osteonecrosis of the Jaw After Teriparatide [Recombinant Human PTH-(1-34)] Therapy
J Rheumatol, August 1, 2009; 36(8): 1835 - 1837.
[Full Text] [PDF]


Home page
Ann OncolHome page
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc., August 1, 2009; 20(8): 1303 - 1317.
[Abstract] [Full Text] [PDF]


Home page
The Journal of RheumatologyHome page
A. A. KHAN, G. K.B. SANDOR, E. DORE, A. D. MORRISON, M. ALSAHLI, F. AMIN, E. PETERS, D. A. HANLEY, S. R. CHAUDRY, B. LENTLE, et al.
Bisphosphonate Associated Osteonecrosis of the Jaw
J Rheumatol, March 1, 2009; 36(3): 478 - 490.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken
Bisphosphonates in Oncology: Rising Stars or Fallen Heroes
Oncologist, February 1, 2009; 14(2): 181 - 191.
[Abstract] [Full Text] [PDF]


Home page
Journal of the American Dental AssociationHome page
P. P. Sedghizadeh, K. Stanley, M. Caligiuri, S. Hofkes, B. Lowry, and C. F. Shuler
Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: An institutional inquiry
J Am Dent Assoc, January 1, 2009; 140(1): 61 - 66.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C. I. Ripamonti, M. Maniezzo, T. Campa, E. Fagnoni, C. Brunelli, G. Saibene, C. Bareggi, L. Ascani, and E. Cislaghi
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan
Ann. Onc., January 1, 2009; 20(1): 137 - 145.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. A. Dimopoulos, E. Kastritis, C. Bamia, I. Melakopoulos, D. Gika, M. Roussou, M. Migkou, E. Eleftherakis-Papaiakovou, D. Christoulas, E. Terpos, et al.
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
Ann. Onc., January 1, 2009; 20(1): 117 - 120.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
N. D. Toussaint, G. J. Elder, and P. G. Kerr
Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue
Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 221 - 233.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Badros, E. Terpos, E. Katodritou, O. Goloubeva, E. Kastritis, E. Verrou, K. Zervas, M. R. Baer, T. Meiller, and M. A. Dimopoulos
Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
J. Clin. Oncol., December 20, 2008; 26(36): 5904 - 5909.
[Abstract] [Full Text] [PDF]


Home page
Cleveland Clinic Journal of MedicineHome page
J. J. CAREY and L. PALOMO
Bisphosphonates and osteonecrosis of the jaw: Innocent association or significant risk?
Cleveland Clinic Journal of Medicine, December 1, 2008; 75(12): 871 - 879.
[Abstract] [Full Text] [PDF]


Home page
J Dent EducHome page
A. Mariotti
Bisphosphonates and Osteonecrosis of the Jaws
J Dent Educ., August 1, 2008; 72(8): 919 - 929.
[Abstract] [Full Text] [PDF]


Home page
AJPHHome page
J. L. Kelsey and I. B. Lamster
Influence of Musculoskeletal Conditions on Oral Health Among Older Adults
Am J Public Health, July 1, 2008; 98(7): 1177 - 1183.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg
Case 9-2008 -- A 65-Year-Old Woman with a Nonhealing Ulcer of the Jaw
N. Engl. J. Med., March 20, 2008; 358(12): 1283 - 1291.
[Full Text] [PDF]


Home page
The OncologistHome page
T. Ibrahim, F. Barbanti, G. Giorgio-Marrano, L. Mercatali, S. Ronconi, C. Vicini, and D. Amadori
Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study
Oncologist, March 1, 2008; 13(3): 330 - 336.
[Abstract] [Full Text] [PDF]


Home page
Journal of the American Dental AssociationHome page
J. T. Grbic, R. Landesberg, S.-Q. Lin, P. Mesenbrink, I. R. Reid, P.-C. Leung, N. Casas, C. P. Recknor, Y. Hua, P. D. Delmas, et al.
Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
J Am Dent Assoc, January 1, 2008; 139(1): 32 - 40.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
G. D. Roodman
Skeletal Imaging and Management of Bone Disease
Hematology, January 1, 2008; 2008(1): 313 - 319.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Jadu, L. Lee, M. Pharoah, D. Reece, and L. Wang
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients
Ann. Onc., December 1, 2007; 18(12): 2015 - 2019.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
S.L. Ruggiero and S.J. Drew
Osteonecrosis of the Jaws and Bisphosphonate Therapy
Journal of Dental Research, November 1, 2007; 86(11): 1013 - 1021.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
J. A. Katzel, P. Hari, and D. H. Vesole
Multiple Myeloma: Charging Toward a Bright Future
CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S.-B. Woo and D. H. Solomon
Bisphosphonate Therapy for Cancer and Prevalence of Inflammatory Jaw Conditions
J Natl Cancer Inst, July 4, 2007; 99(13): 986 - 987.
[Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
N. G. Shenker and A. S. M. Jawad
Bisphosphonates and osteonecrosis of the jaw
Rheumatology, July 1, 2007; 46(7): 1049 - 1051.
[Full Text] [PDF]


Home page
JCOHome page
R. A. Kyle, G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson
American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma
J. Clin. Oncol., June 10, 2007; 25(17): 2464 - 2472.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
B. G. M. Durie and IMWG
Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement
Mayo Clin. Proc., April 1, 2007; 82(4): 516 - 517.
[Full Text] [PDF]


Home page
Ann OncolHome page
D Aguiar Bujanda, U Bohn Sarmiento, M. Cabrera Suarez, and J Aguiar Morales
Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis
Ann. Onc., March 1, 2007; 18(3): 556 - 560.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
C. D Krueger, P. M West, M. Sargent, A. E Lodolce, and A S. Pickard
Bisphosphonate-Induced Osteonecrosis of the Jaw
Ann. Pharmacother., February 1, 2007; 41(2): 276 - 284.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
F. C. Kelleher, M. McKenna, C. D. Collins, and J. P. Crown
A Potential Anatomic Cause of Mandibular Osteonecrosis in Patients Receiving Bisphosphonate Treatment
Mayo Clin. Proc., January 1, 2007; 82(1): 134 - 134.
[Full Text] [PDF]


Home page
The OncologistHome page
C. Gridelli
The Use of Bisphosphonates in Elderly Cancer Patients
Oncologist, January 1, 2007; 12(1): 62 - 71.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Tosi, E. Zamagni, D. Cangini, P. Tacchetti, F. Di Raimondo, L. Catalano, A. D'Arco, S. Ronconi, C. Cellini, M. Offidani, et al.
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Blood, December 15, 2006; 108(12): 3951 - 3952.
[Full Text] [PDF]


Home page
The OncologistHome page
T. A. Guise
Bone Loss and Fracture Risk Associated with Cancer Therapy
Oncologist, November 1, 2006; 11(10): 1121 - 1131.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G Sanna, L Preda, R Bruschini, M Cossu Rocca, S Ferretti, L Adamoli, E Verri, L Franceschelli, A Goldhirsch, and F Nole
Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
Ann. Onc., October 1, 2006; 17(10): 1512 - 1516.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
M. J. Somerman and L. K. McCauley
Bisphosphonates: Sacrificing the Jaw to Save the Skeleton?
IBMS BoneKEy, September 1, 2006; 3(9): 12 - 18.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, et al.
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Mayo Clin. Proc., August 1, 2006; 81(8): 1047 - 1053.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
B. Mehrotra and S. Ruggiero
Bisphosphonate Complications Including Osteonecrosis of the Jaw
Hematology, January 1, 2006; 2006(1): 356 - 360.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online